A groundbreaking artificial intelligence tool has been unveiled to predict how patients with advanced bowel cancer will respond to a newly introduced NHS medication, potentially sparing thousands from undergoing treatments that prove ineffective against their specific cancers. Researchers from the Institute of Cancer Research in London and the RCSI University of Medicine and Health Sciences in Dublin have developed this innovative method, aiming to enhance personalized care and reduce unnecessary side-effects.
Study Details and Patient Impact
The research focused on 117 European bowel cancer patients who had previously received chemotherapy and bevacizumab, a drug approved by the NHS in December. Bevacizumab functions by inhibiting tumour growth by depriving cancers of essential proteins, but it is effective only for a limited subset of patients and can cause serious adverse effects, including blood clots and gastrointestinal complications. In the United Kingdom alone, nearly 10,000 cases of advanced bowel cancer are diagnosed annually, with a notable increase among young adults. Bowel cancer ranks as the second deadliest cancer, following lung cancer, with survival rates dropping to as low as 10% over five years for advanced stages, compared to 98% when detected early.
How PhenMap Works
Utilizing PhenMap, an AI tool that combines "phenotype" (observable traits) with "mapping," scientists integrated complex genetic data from tumours to analyze patient responses. This approach enabled the identification of patterns in drug reactions and pinpointed a group of patients with a specific gene mutation who faced a high risk of negative outcomes. The findings offer a promising step toward tailoring treatments, as the tool can discern which individuals are least likely to benefit from bevacizumab, thereby avoiding futile therapies.
Expert Insights and Future Directions
Anguraj Sadanandam, a professor in stratification and precision medicine at the Institute of Cancer Research, emphasized the significance of this development. He noted that while bevacizumab provides a new option for patients with metastatic bowel cancer, most will not respond positively, leading to unnecessary suffering from side-effects. Sadanandam explained that PhenMap leverages advanced AI to process vast amounts of intricate data, revealing hidden clues within tumours that human analysis might miss. However, he cautioned that further validation through larger patient cohorts is necessary before clinical implementation.
The research team now plans to expand the study by increasing patient samples and exploring the tool's applicability to other cancer types. Sadanandam expressed hope that this method will eventually lead to a clinical test, ensuring patients receive personalized treatments with the highest efficacy. This advancement underscores the growing role of AI in oncology, aiming to improve outcomes and quality of life for those battling aggressive cancers.
